Oxford Biomedica Logo
Scientist microscope

Oxford BioMedica: Notice of FY2009 Preliminary Results - 17/02/2010

2010/OB/06

Oxford, UK –17 February 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that it will be releasing its preliminary results for the twelve months ended 31 December 2009 on Wednesday, 10 March 2010.

Analyst meeting: An analyst briefing will be held at 10:30 am on Wednesday, 10 March 2010 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
 

Web cast: Simultaneously to the analyst briefing at 10:30 am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please follow link: http://mediaserve.buchanan.uk.com/2010/oxb100310/registration.asp approximately 10 minutes (10:20 am) before the start of the briefing. This will also be available for replay shortly after the presentation

- Ends -

Notes to editors

1.

Oxford BioMedica plc
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen-Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk
 
For further information please contact:
Oxford BioMedica plc
Lara Mott, Head of Corporate Communications		 Tel: +44 (0)1865 783 000
JPMorgan Cazenove Limited
James Mitford/Gina Gibson		 Tel: +44 (0)20 7588 2828
M: Communications Media/Financial Enquiries
Emma Thompson/Rob Newman/Ben Simons		 Tel: +44 (0)20 7920 2345
US Enquiries
Thomas Fechtner
The Trout Group LLC		 Tel: +1 646 378 2900